+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Future of Pulmonary Embolism R&D Pipeline Drugs and Companies- Analysis of Global Pulmonary Embolism Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4745224
  • Report
  • January 2019
  • Region: Global
  • 40 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • Dong-A Socio Holdings
  • ST Pharm Co.,Ltd.
  • TeaRx Ltd.
  • Verseon Corp
  • MORE
The global demand for Pulmonary Embolism treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Pulmonary Embolism pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Pulmonary Embolism pipeline companies from advancing their products into Phase 3 or Phase 4.

Pulmonary Embolism Report Description

The H1- 2019 pipeline review report on Pulmonary Embolism pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Pulmonary Embolism pipeline compounds.

The Pulmonary Embolism pipeline guide presents information on all active drugs currently being developed for Pulmonary Embolism. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Pulmonary Embolism pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Pulmonary Embolism drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Pulmonary Embolism product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Pulmonary Embolism pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Pulmonary Embolism pipeline report includes
  • An overview of Pulmonary Embolism disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of pipeline compounds
  • Company wise list of pipeline compounds
  • Mechanism of Action wise pipeline compounds
For each pipeline product, the following details are provided
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Pulmonary Embolism pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Pulmonary Embolism pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into the market through in-depth strategic analysis review
  • Know the list of companies participating in global Pulmonary Embolism pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • Dong-A Socio Holdings
  • ST Pharm Co.,Ltd.
  • TeaRx Ltd.
  • Verseon Corp
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Pulmonary Embolism Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology

3. Executive Summary
3.1 Pulmonary Embolism Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Pulmonary Embolism pipeline, H1- 2019
3.5 Mechanism of Action wise Pulmonary Embolism Pipeline Candidates

4. Daiichi Sankyo Co Ltd Pulmonary Embolism Pipeline Details
4.1 Daiichi Sankyo Co Ltd Business Profile
4.2 Daiichi Sankyo Co Ltd Pulmonary Embolism Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5. Dong-A Socio Holdings Pulmonary Embolism Pipeline Details
5.1 Dong-A Socio Holdings Business Profile
5.2 Dong-A Socio Holdings Pulmonary Embolism Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6. ST Pharm Co.,Ltd. Pulmonary Embolism Pipeline Details
6.1 ST Pharm Co.,Ltd. Business Profile
6.2 ST Pharm Co.,Ltd. Pulmonary Embolism Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7. Tasly Phar. International Co., Ltd Pulmonary Embolism Pipeline Details
7.1 Tasly Phar. International Co., Ltd Business Profile
7.2 Tasly Phar. International Co., Ltd Pulmonary Embolism Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8. TeaRx Ltd. Pulmonary Embolism Pipeline Details
8.1 TeaRx Ltd. Business Profile
8.2 TeaRx Ltd. Pulmonary Embolism Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9. Verseon Corp Pulmonary Embolism Pipeline Details
9.1 Verseon Corp Business Profile
9.2 Verseon Corp Pulmonary Embolism Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10. Latest Pulmonary Embolism Drug Pipeline Developments, 2019

11. Appendix
11.1 About Us
11.2 Sources and Methodology
11.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Daiichi Sankyo Co Ltd
  • Dong-A Socio Holdings
  • ST Pharm Co.,Ltd.
  • Tasly Phar. International Co., Ltd
  • TeaRx Ltd.
  • Verseon Corp
Note: Product cover images may vary from those shown
Adroll
adroll